2-Methylindoline pharma grade API, assigned CAS 6872-06-6 (2-methyl-2,3-dihydro-1H-indole), molecular formula C9H11N, and relative molecular mass 133.19, is a substituted indoline supplied as the free base. The C-2 position is a stereogenic centre; unless otherwise specified, the standard pharmaceutical grade is the racemic form, and enantiomerically enriched lots require a chiral HPLC release method because the two enantiomers differ in optical rotation and may differ in receptor-binding or metabolic stability. No dedicated monograph is published in Ph. Eur. 11.0, USP-NF 2024, or JP 18; therefore, this material is controlled against a manufacturer’s specification derived from ICH Q6A decision trees and the impurity frameworks of ICH Q3A/Q3C/Q3D. The free base is a mobile liquid at ambient temperature, which distinguishes it from many crystalline APIs and imposes a direct barrier to conventional dry granulation and direct compression unless the API is first adsorbed, converted to a salt, or processed by melt granulation.

What Separates 2-Methylindoline from Indoline, 1-Methylindoline, and 2-Methylindole in Downstream Processing?

In comparison with indoline, the C-2 methyl group increases boiling point and lipophilicity while introducing a stereogenic centre; this shift changes retention in both gas and liquid chromatography and modifies the free base solubility in aqueous buffers. The N-H function remains available for protonation and salt formation, unlike 1-methylindoline, in which N-substitution abolishes the secondary amine proton and removes the possibility of simple hydrochloride or sulfate salt formation at the indoline nitrogen. Against 2-methylindole, the saturated 2,3-bond of 2-methylindoline reduces aromatic stabilisation and alters chemical stability; the indoline ring is more likely to undergo aerial oxidation to coloured degradation products, while the indole aromatic system is more susceptible to electrophilic substitution. For gas-chromatographic identification, a 5% phenyl–95% methylpolysiloxane capillary column of 30 m × 0.25 mm × 0.25 µm separates these analogues by boiling-point and N-substitution differences; for impurity profiling, reversed-phase HPLC on a C18 column with a pH 2.5 mobile phase suppresses secondary-amine peak tailing. The selection of 2-methylindoline over indoline or 1-methylindoline is therefore not only a structural variation but also a control-strategy variation: chiral identity, salt stoichiometry, and oxidative degradant limits differ.

Analytical control for release and stability must address the liquid state and oxidative lability. Samples should be handled under a nitrogen or argon overlay and drawn with glass or PTFE-lined stainless steel equipment; prolonged exposure to laboratory air increases the intensity of yellow discolouration and produces secondary-amine oxidation products. Identification is confirmed by infrared spectrophotometry against a qualified reference lot and by gas chromatography retention time, while assay is generally performed by validated high-performance liquid chromatography with UV detection at a wavelength selected from the compound absorption maximum. Method validation must include forced-degradation studies under ICH Q1A to establish peak purity with a photodiode-array detector; specificity is particularly important because the N-H and C-2 methyl groups create a chiral impurity profile that may not be resolved by area-percent HPLC alone. When enantiopure drug substance is claimed, enantiomeric excess should be reported by chiral HPLC or GC and not inferred from non-chiral assay.

Tablet, capsule, and granule presentations cannot be manufactured by direct compression because the free base is not a free-flowing solid. Two production-scale routes are available for solid oral dosage forms. In the first route, the liquid is adsorbed onto granulation-grade microcrystalline cellulose, colloidal silicon dioxide, or porous calcium silicate in a high-shear mixer; an impeller tip speed in the range of 2.5–5.0 m/s is used to distribute the oil without excessive heating. The wet mass is then vacuum-dried at a product temperature not exceeding 40 °C to limit volatilisation and oxidative discolouration. Loss on drying is checked by USP <731>, granule flow by USP <1174>, and particle size by laser diffraction under ISO 13320-1:2020. In the second route, the free base is converted to a salt, such as the hydrochloride or hydrogen sulfate, isolated by crystallisation, and milled to a target D90 of 150 µm or below for capsule filling or tablet compression. Salt formation must be confirmed by X-ray powder diffraction, because incomplete salt formation leaves residual free base that can soften gelatin capsules or interfere with tablet hardness. For tablets, a compaction study using an instrumented press should record ejection force and tensile strength; the lubricant concentration should be kept at or below 1.0% w/w unless a compatibility study shows no dissolution slowdown. Published pilot-scale data for this specific liquid-to-solid conversion are limited; the operating ranges described for comparable indoline bases should be verified in a development batch before scale-up.

Granule formulations should avoid aqueous granulation of the free base unless the API is protonated and held in solution at a controlled pH. Neutralisation during drying can cause oiling-out and uneven potency; near-infrared process analytical technology can detect residual free-base domains in wet granules. For capsules, hard gelatin may be softened by the free base, so HPMC capsules or a dry adsorbed intermediate are preferred at high loading. Disintegration and dissolution should be checked by USP <701> and USP <711>; because the API has a weakly basic amine, dissolution media may require pH adjustment and surfactant if the compound shows low aqueous solubility.

When Injectable Presentation Is Required, Bioburden, Endotoxin, and Oxidative Stability Control the Critical Quality Attributes

For injectable formulations, the free base is usually converted to a water-soluble salt and buffered to an acidic pH at which the secondary amine is protonated; the optimum pH is selected from phase-solubility and forced-degradation data, with typical development studies covering pH 3.0–5.0. The API is non-sterile as supplied, so the finished dosage form must be sterilised. Terminal sterilisation at 121 °C for 15 min is acceptable only if thermal stress produces no unspecified degradation product above 0.05% and no shift in chiral purity. If terminal sterilisation is not acceptable, aseptic filtration through a 0.22 µm membrane is required, and the compounding vessel should be blanketed with nitrogen because the indoline nitrogen is susceptible to oxidative degradation. Bacterial endotoxin limits are assigned from USP <85> on the basis of the maximum adult dose; the API lot should be supplied with a bioburden certificate not exceeding 100 CFU/g and an endotoxin result not exceeding the release limit agreed with the drug product manufacturer. The formulation should include an antioxidant or chelating agent only after forced-degradation studies demonstrate that the additive does not form nitrogen-adduct impurities.

Release Specification and Compliance Checklist for Pharma Grade 2-Methylindoline

Because no harmonized monograph exists, the following controls are applied as a manufacturer’s interim specification. Acceptance limits are derived from ICH Q6A decision tree approaches and general monograph requirements for liquid APIs; method validation follows ICH Q2(R2).

Batch release is not complete without a stability-indicating assay; real-time stability under ICH Q1A and intermediate conditions under ICH Q1B should be assigned based on the intended container closure system. Published data for this specific configuration may be limited; therefore, the specification should be revised as additional stability lots are produced.

Storage and packaging of the free base require amber glass or epoxy-lined steel containers under a nitrogen or argon headspace. Controlled room temperature 20–25 °C is appropriate; excursions to 15–30 °C are acceptable only if closure integrity is verified by USP <671> and if nitrogen positive pressure is maintained during repeated sampling. The substance should not be combined with strong oxidising agents, peroxides, anhydrides, epoxides, or acid chlorides within the same unit operation, because the secondary amine can react exothermically and form impurities or degrade. The free base should be dispensed under local exhaust ventilation; personnel exposure limits are substance-specific and should be taken from the current SDS. No conclusion regarding long-term toxicology or environmental safety is implied by the batch release data.